MedTrace Logo

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

NCT04666688 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2025-02-12

No results posted yet for this study

Summary

A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors

Conditions

Interventions

DRUG

LYT-200

monoclonal antibody (mAb), targeting galectin-9 protein

DRUG

Tislelizumab

anti-PD-1 monoclonal antibody

DRUG

Gemcitabine/nab-paclitaxel

chemotherapy

Sponsors & Collaborators

Principal Investigators

  • Aleksandra Filipovic, MD, Ph.D. · PureTech Health

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-15
Primary Completion
2024-12-12
Completion
2024-12-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04666688 on ClinicalTrials.gov